ATOS Latest Press Releases

-- October 19, 2026 --

Atossa Therapeutics Common Stock to Begin Trading with Stapled Contingent Value Rights After Close of Business Today PRNewswire 8:01 AM

-- October 9, 2026 --

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value PRNewswire 8:00 AM

-- September 29, 2026 --

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher PRNewswire 8:01 AM

-- September 24, 2026 --

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging PRNewswire 8:01 AM

-- August 7, 2026 --

Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update PRNewswire 8:45 AM

-- July 28, 2026 --

Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer PRNewswire 8:30 AM

-- July 21, 2026 --

Atossa Therapeutics Announces Presentation of Mechanism-Driven (Z)-Endoxifen Data in McCune-Albright Syndrome at AACR Special Conference on Rare Cancers PRNewswire 8:30 AM

-- June 12, 2026 --

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds PRNewswire 5:31 PM

-- June 11, 2026 --

Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds PRNewswire 8:00 AM

-- May 27, 2026 --

Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial PRNewswire 8:30 AM

Market Data Delayed 15 Minutes